With the identification of ALK as a common driver of NB in 2008, the results of early crizotinib trials in NSCLC provided the rationale for further evaluation in other ALK-driven cancers such as ALCL and ALK-positive NB. This evidence concerns the gene ALK and anaplastic large cell lymphoma.